rpl-9 Antibody

What is RPL9 and why is it relevant for research?

RPL9 (ribosomal protein L9) is a component of the 60S subunit of the ribosome, belonging to the L6P family of ribosomal proteins. While traditionally viewed as essential for protein synthesis machinery, recent research has uncovered extra-ribosomal functions, particularly in cancer biology. RPL9 acts as a cancer-promoting RNA-binding protein (RBP) that can bind to specific miRNAs and translocate them into exosomes, thereby affecting miRNA profiles within exosomes and recipient cells . This makes RPL9 a valuable research target for understanding novel mechanisms in cancer progression, particularly in hepatocellular carcinoma (HCC), where it may contribute to cell proliferation, migration, and invasion processes .

What applications are RPL9 antibodies validated for?

RPL9 antibodies are validated for multiple laboratory applications crucial for cellular and molecular biology research:

Antibodies have been specifically tested and confirmed to work with multiple cell lines including HeLa, HEK-293, Jurkat, A549, HepG2, MCF-7, U2OS, HSC-T6, and NIH/3T3 cells , providing researchers flexibility across different experimental models.

What is the molecular weight of RPL9 and how does this affect antibody detection?

RPL9 has a calculated molecular weight of approximately 22 kDa, which matches its observed molecular weight in experimental settings . When working with RPL9 antibodies, it's important to consider this size when interpreting Western blot results. The consistent calculated and observed weights suggest minimal post-translational modifications affecting size. When designing experiments, researchers should use appropriate percentage gels (typically 4-12% PAGE gradient gels are suitable as used in published protocols ) to ensure optimal separation and visualization of this relatively small protein. For Western blot methodology, standard protocols including boiling samples in Laemmli protein sample loading buffer prior to gel separation are effective for RPL9 detection .

How does RPL9 function in exosomal miRNA transport and cancer progression?

RPL9 exhibits significant extra-ribosomal functions in cancer biology, particularly in hepatocellular carcinoma (HCC). Research has revealed that RPL9 serves as a cancer-promoting RNA-binding protein that can directly bind to specific miRNAs, including miR-24-3p and miR-185-5p, and facilitate their transport into exosomes . This mechanism represents a novel pathway for intercellular communication in cancer progression.

The process works as follows:

• RPL9 binds directly to specific miRNAs (confirmed through RNA immunoprecipitation)

• This complex is packaged into exosomes

• Exosomes are released and taken up by recipient cells

• The transported miRNAs then affect gene expression in recipient cells

Experimental evidence shows that RPL9 knockdown significantly suppresses HCC cell proliferation, migration, and invasion capabilities . Additionally, it reduces the biological activity of HCC-derived exosomes, confirming RPL9's role in exosome-mediated cancer progression. Overexpression studies further demonstrate that elevated miR-24-3p in cells increases its accumulation in exosomes while simultaneously upregulating RPL9, creating a potential feedback mechanism that enhances exosome bioactivity .

For researchers studying cancer biology, targeting RPL9 using validated antibodies in co-immunoprecipitation experiments can help elucidate protein-RNA interactions central to these pathways.

What are the methodological considerations for RPL9 antibody use in ribosome purification studies?

Ribosome purification using RPL9-tagged proteins represents an advanced approach for studying translational regulation. Both RPL-4 and RPL-9 mediated ribosome purification methods work on the same principle: ribosomes and their associated mRNAs are isolated via a specifically tagged protein of the large subunit .

When implementing this technique:

• Antibody selection: Choose an antibody with validated specificity for the tagged RPL9 construct. Antibodies against common tags (FLAG, GFP) may be used if working with tagged RPL9 constructs similar to those described in research protocols (e.g., pLVX-Flag-RPL9-AcGFP) .

• Expression system considerations: When using lentiviral vectors for expressing tagged RPL9 (such as pLVX-AcGFP-N1), ensure proper incorporation into functional ribosomes by validating ribosome assembly through sucrose gradient analysis.

• Purification conditions: Optimize buffer conditions to maintain ribosome integrity while allowing efficient antibody binding. Standard approaches use buffer systems containing Tris base (15 mM) and Glycine (192 mM) .

• Controls: Include untagged ribosome preparations and isotype controls to assess purification specificity.

When analyzing results, researchers should confirm that purified ribosomes maintain translational competence to ensure the tagged RPL9 doesn't disrupt normal ribosomal function.

How can RPL9 antibodies be used to investigate its role in cancer models?

RPL9 antibodies serve as critical tools for investigating its oncogenic functions in various cancer models:

• Expression analysis: Immunohistochemistry (IHC) using anti-RPL9 antibodies (diluted 1:200) can assess RPL9 expression in xenograft tumor tissues to correlate expression with tumor progression . This approach has been validated in nude mice models using MHCC97H and Huh7 cell lines with RPL9 knockdown.

• Mechanism studies: Co-immunoprecipitation combined with RNA sequencing can identify RPL9-bound miRNAs involved in cancer progression. Research has identified miR-24-3p and miR-185-5p as key miRNAs bound by RPL9 that influence cancer cell behavior .

• Functional validation: Immunofluorescence assays can confirm RPL9's ability to carry miRNAs into recipient cells via exosomes, establishing its role in intercellular communication .

• Combinatorial approaches: For comprehensive analysis, researchers should combine antibody-based detection with functional assays after manipulating RPL9 expression. For example, using lentiviral vectors containing RPL9 knockdown constructs (target sequence: gaTG GTA TCT ATG TCT CTG AA) or overexpression constructs in cancer cell lines, followed by phenotypic assays and antibody-based protein detection .

When designing such studies, researchers should consider both monoclonal antibodies for high specificity and polyclonal antibodies for improved detection sensitivity, depending on the specific application requirements.

What are the optimal protocols for Western blotting using RPL9 antibodies?

For optimal Western blot detection of RPL9, follow these methodological considerations:

• Sample preparation:

  • Collect cells or hand-pick tissue samples

  • Prepare lysates by boiling in Laemmli protein sample loading buffer

  • Use fresh samples when possible to prevent protein degradation

• Gel selection and running conditions:

  • Use 4-12% PAGE gradient gels for optimal separation of the 22 kDa RPL9 protein

  • Run at standard voltage (typically 100-120V) in standard running buffer

• Transfer conditions:

  • Use blotting buffer containing 15 mM Tris base and 192 mM Glycine

  • Transfer at 100V for 1 hour or 30V overnight at 4°C for efficient protein transfer

• Antibody dilution and incubation:

  • Primary antibody dilutions vary by manufacturer:

    • Monoclonal antibodies: 1:5000-1:50000

    • Polyclonal antibodies: 1:500-1:2000

  • Incubate primary antibody overnight at 4°C for optimal binding

  • Use appropriate secondary antibodies compatible with detection system

• Detection system:

  • Infrared detection systems like Odyssey Fc Imaging System with IRDye secondary antibodies provide excellent results

  • Chemiluminescence detection also works well with appropriate HRP-conjugated secondary antibodies

Always include appropriate positive controls from validated cell lines (HeLa, HEK-293, Jurkat, A549, HepG2, MCF-7, U2OS, HSC-T6, or NIH/3T3) and molecular weight markers to confirm specificity.

What conditions are recommended for immunohistochemistry and immunofluorescence with RPL9 antibodies?

For successful immunohistochemistry (IHC) and immunofluorescence (IF) experiments using RPL9 antibodies:

Immunohistochemistry Protocol:

• Antigen retrieval:

  • Use TE buffer pH 9.0 (preferred) or citrate buffer pH 6.0 as alternative

  • Heat-induced epitope retrieval is recommended (typically 95-100°C for 15-20 minutes)

• Antibody dilutions:

  • Anti-RPL9 antibodies: 1:50-1:500

  • For xenograft tumor tissue samples, 1:200 dilution with overnight incubation at 4°C has been validated

• Detection systems:

  • Standard DAB detection systems are compatible

  • For quantification, integrated optical density (IOD) scoring using ImageJ software is recommended

Immunofluorescence Protocol:

• Sample preparation:

  • Cell fixation: 4% paraformaldehyde for 15 minutes

  • Permeabilization: 0.1% Triton X-100 for 10 minutes

• Antibody dilutions:

  • IF-P applications: 1:200-1:800 for most RPL9 antibodies

  • For co-localization studies with exosomal markers, optimize dilutions for each antibody

• Visualization:

  • Use appropriate fluorescent secondary antibodies

  • Include DAPI nuclear counterstain

  • Capture images using a cell imaging system like EVOS FL Auto (Thermo Fisher Scientific)

For both applications, include proper negative controls (isotype controls or secondary antibody only) and positive controls (tissues/cells known to express RPL9, such as mouse cerebellum tissue which has been validated for both IHC and IF-P) .

How should RPL9 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of RPL9 antibodies is critical for maintaining their performance and extending their usable lifespan:

• Storage temperature:

  • Store at -20°C for long-term preservation

  • Antibodies are typically stable for one year after shipment when stored correctly

  • For antibodies in liquid form with glycerol (e.g., PBS with 0.02% sodium azide and 50% glycerol), aliquoting is unnecessary for -20°C storage

• Buffer composition:

  • Most commercial RPL9 antibodies are supplied in PBS with preservatives

  • Common formulations include PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Some preparations may contain small amounts (0.1%) of BSA as a stabilizer

• Freeze-thaw considerations:

  • Minimize freeze-thaw cycles even for glycerol-containing preparations

  • For concentrated antibodies without glycerol, aliquot upon receipt to avoid repeated freeze-thaw cycles

• Working dilution preparation:

  • Prepare working dilutions immediately before use

  • Dilute in appropriate buffer (PBS with 0.1% BSA is typically suitable)

  • Do not store diluted antibody for extended periods

• Contamination prevention:

  • Use sterile technique when handling antibodies

  • Be aware that sodium azide is a common preservative and is toxic and incompatible with certain applications (particularly those involving HRP)

Following these storage and handling guidelines will help ensure consistent experimental results and maximize the useful lifespan of your RPL9 antibodies.

What are common issues when working with RPL9 antibodies and how can they be resolved?

Researchers may encounter several challenges when working with RPL9 antibodies. Here are common issues and their solutions:

• Weak or no signal in Western blot:

  • Issue: Insufficient protein loading or antibody concentration

  • Solution: Increase protein amount (10-30 μg per lane) and/or optimize primary antibody concentration; consider using monoclonal antibodies with higher dilutions (1:5000) or polyclonal antibodies with lower dilutions (1:500)

  • Issue: Inadequate transfer

  • Solution: Verify transfer efficiency with reversible protein staining; adjust transfer time/buffer composition using Tris base (15 mM) and Glycine (192 mM)

• High background in immunostaining:

  • Issue: Non-specific binding

  • Solution: Increase blocking time/concentration; optimize antibody dilution (1:50-1:500 for IHC; 1:200-1:800 for IF-P) ; include additional washing steps

  • Issue: Cross-reactivity

  • Solution: Use highly specific monoclonal antibodies; validate antibody specificity with positive and negative controls

• Inconsistent results between experiments:

  • Issue: Antibody degradation

  • Solution: Ensure proper storage at -20°C; verify storage buffer conditions (PBS with 0.02% sodium azide and 50% glycerol pH 7.3)

  • Issue: Protocol variations

  • Solution: Standardize protocols; document exact conditions for successful experiments

• Problems detecting RPL9 in specific tissues/cells:

  • Issue: Low expression levels

  • Solution: Use more sensitive detection methods; consider signal amplification systems

  • Issue: Epitope masking

  • Solution: Try different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

• Issues with co-localization studies:

  • Issue: Signal overlap limitations

  • Solution: Use super-resolution microscopy; optimize fixation protocols to preserve subcellular structures; carefully select compatible fluorophores

Always titrate new antibody batches in your specific experimental system to determine optimal conditions, as recommended by manufacturers .

How can researchers validate the specificity of RPL9 antibodies in their experimental systems?

Thorough validation of RPL9 antibody specificity is crucial for generating reliable research data. Implement these approaches:

• Positive and negative controls:

  • Use cell lines with confirmed RPL9 expression as positive controls (HeLa, HEK-293, Jurkat, A549, HepG2, MCF-7, U2OS, HSC-T6, or NIH/3T3 cells)

  • For negative controls, use:

    • RPL9 knockdown samples generated using validated shRNA constructs (target sequence: gaTG GTA TCT ATG TCT CTG AA)

    • Secondary antibody-only controls

    • Isotype controls matching the primary antibody host/isotype

• Multiple detection methods:

  • Compare results across different applications (WB, IHC, IF) to confirm consistent detection patterns

  • Verify molecular weight in Western blots matches the expected 22 kDa size

• Immunoprecipitation validation:

  • Perform IP followed by mass spectrometry to confirm the identity of the pulled-down protein

  • Validate with reverse IP using different antibodies targeting the same protein

• Genetic approaches:

  • Establish stable knockdown cell lines using lentiviral vectors with RPL9-targeted shRNAs

  • Create overexpression systems using vectors like pLVX-Flag-RPL9-AcGFP

  • Compare antibody reactivity between these modified systems

• Cross-antibody validation:

  • Compare results using different RPL9 antibodies (monoclonal vs. polyclonal, antibodies recognizing different epitopes)

  • Agreement between different antibodies increases confidence in specificity

• Peptide competition:

  • Pre-incubate antibody with purified RPL9 protein or immunogenic peptide

  • Specific signal should be significantly reduced or eliminated

These comprehensive validation approaches will ensure that experimental outcomes reflect genuine RPL9 biology rather than non-specific interactions or artifacts.

How can RPL9 antibodies be utilized in studying ribosome biogenesis and extra-ribosomal functions?

RPL9 antibodies can be powerful tools for investigating both canonical ribosome biogenesis and emerging extra-ribosomal functions:

• Ribosome assembly analysis:

  • Use RPL9 antibodies in conjunction with sucrose gradient fractionation to trace incorporation into pre-ribosomal particles

  • Immunoprecipitation of RPL9 followed by rRNA analysis can reveal association with specific assembly intermediates

  • Compare wild-type vs. stress conditions to understand regulation of ribosome assembly

• Nucleolar vs. cytoplasmic localization:

  • Immunofluorescence using optimized protocols (1:200-1:800 dilution) can reveal subcellular distribution

  • Co-staining with nucleolar markers helps distinguish assembly-related vs. mature ribosome-associated RPL9

  • Track dynamic changes in localization following cellular stresses like nutrient deprivation

• Extra-ribosomal RNA interactions:

  • RNA immunoprecipitation (RIP) using RPL9 antibodies can identify bound miRNAs beyond the ribosomal context

  • Validated examples include miR-24-3p and miR-185-5p in cancer contexts

  • Compare RIP results between cytoplasmic and exosomal fractions to track RNA transport processes

• Exosome characterization:

  • Co-immunoprecipitation of RPL9 with exosomal markers confirms packaging mechanisms

  • Immunofluorescence showing co-localization with exosome formation sites provides spatial context

  • RPL9 immunoblotting of purified exosomal fractions quantifies enrichment in these vesicles

• Interaction network mapping:

  • Proximity labeling approaches combining RPL9 antibodies with mass spectrometry can identify novel interaction partners

  • Compare interaction networks between normal and cancer cells to identify pathological associations

These applications provide a comprehensive toolkit for dissecting RPL9's diverse cellular functions, particularly its emerging roles in RNA transport and cancer progression through exosomal pathways .

What considerations are important when designing RPL9 knockdown or overexpression studies with antibody-based validation?

When manipulating RPL9 expression levels for functional studies, careful experimental design with appropriate antibody-based validation is essential:

• Knockdown strategy optimization:

  • Use validated shRNA sequences (e.g., target sequence: gaTG GTA TCT ATG TCT CTG AA)

  • Construct lentiviral vectors based on proven backbones like GV493

  • Include appropriate control lentiviruses expressing only reporter genes (e.g., gcGFP; target sequence: TTC TCC GAA CGT GTC ACG T)

  • Verify knockdown efficiency by Western blot using optimized antibody dilutions (1:5000-1:50000 for monoclonal or 1:500-1:2000 for polyclonal antibodies )

• Overexpression construct design:

  • Generate tagged constructs (e.g., N-terminal Flag-tagged RPL9 in pLVX-AcGFP-N1)

  • Confirm expression using antibodies against both RPL9 and the fusion tag

• Cell line selection and validation:

  • Choose cell lines with documented RPL9 expression (HeLa, HEK-293, Jurkat, A549, HepG2, MCF-7, U2OS, HSC-T6, NIH/3T3)

  • For cancer studies, MHCC97H and Huh7 cell lines have validated protocols

  • Assess baseline expression levels before manipulation using calibrated Western blot analysis

• Functional assessment approaches:

  • Monitor incorporation into ribosomes using sucrose gradient fractionation followed by RPL9 immunoblotting

  • Assess effects on global translation using metabolic labeling techniques

  • For cancer-related studies, evaluate proliferation, migration, and invasion capabilities

  • Quantify changes in exosome composition and function

• Antibody-based validation checkpoints:

  • Confirm knockdown/overexpression at protein level using Western blot

  • Verify subcellular localization changes using immunofluorescence (1:200-1:800 dilution)

  • For tumor xenograft models, validate expression changes by immunohistochemistry (1:200 dilution)

• Controls and normalization:

  • Include rescue experiments to confirm specificity of observed phenotypes

  • Use established housekeeping genes for normalization in Western blots

  • Quantify results using integrated optical density (IOD) scoring with ImageJ software

By following these guidelines, researchers can generate robust manipulations of RPL9 expression with proper validation using antibody-based techniques.

How might RPL9 antibodies contribute to emerging research on cancer biomarkers and therapeutics?

RPL9 antibodies are poised to play critical roles in advancing cancer biomarker development and therapeutic strategies:

• Exosomal biomarker development:

  • RPL9 is highly expressed in serum exosomes of hepatocellular carcinoma patients compared to those with benign liver disease

  • Antibody-based capture and detection of RPL9-enriched exosomes could serve as a minimally invasive diagnostic approach

  • Quantitative assessment of RPL9 levels in patient-derived exosomes may correlate with disease progression or treatment response

• Therapeutic target validation:

  • Immunohistochemical analysis using RPL9 antibodies can map expression patterns across tumor types and stages

  • Correlation of RPL9 levels with patient outcomes can establish its prognostic value

  • Antibody-based screening systems can identify small molecules that disrupt RPL9's interaction with specific miRNAs

• Molecular mechanism elucidation:

  • Immunoprecipitation combined with mass spectrometry can identify novel RPL9 binding partners in cancer contexts

  • ChIP-seq approaches using RPL9 antibodies may reveal unexpected chromatin associations

  • Proximity labeling techniques can map the complete RPL9 interactome in normal versus cancer cells

• Therapeutic antibody development:

  • Research-grade antibodies provide crucial validation for developing therapeutic antibodies targeting RPL9

  • Internalized antibody conjugates could potentially disrupt RPL9's extra-ribosomal functions while sparing essential translation activities

  • Antibody-based imaging could guide surgical interventions by mapping RPL9-enriched tumor regions

• Combinatorial therapy approaches:

  • Antibody-based screens can identify synergistic drug combinations that target RPL9-dependent pathways

  • Monitoring RPL9 levels during treatment using validated antibodies can assess treatment efficacy

  • RPL9 immunostaining patterns may predict responsiveness to specific therapeutic regimens

These applications highlight how research antibodies against RPL9 are building the foundation for translational advances in cancer diagnostics and treatment strategies.

What are the emerging technical advances in antibody-based detection of RPL9 in complex biological samples?

The field of RPL9 detection is benefiting from several technical innovations that enhance sensitivity, specificity, and throughput:

• Single-cell antibody-based proteomics:

  • Integration of RPL9 antibodies into CyTOF (mass cytometry) panels enables simultaneous detection of multiple markers at single-cell resolution

  • Combining with RNAseq data allows correlation between RPL9 protein levels and transcriptional states

  • Spatial proteomics approaches can map RPL9 distribution within tumor microenvironments

• Proximity ligation assays (PLA):

  • Enhanced detection of RPL9 interactions with miRNAs or protein partners

  • Visualization of specific complexes in situ with single-molecule sensitivity

  • Particularly valuable for detecting transient interactions in the exosome formation pathway

• Super-resolution microscopy applications:

  • Nanoscale localization of RPL9 using fluorophore-conjugated antibodies

  • Distinction between ribosome-associated and free RPL9 pools

  • Co-localization with exosomal markers at previously unresolvable scales

• Microfluidic antibody arrays:

  • High-throughput screening of RPL9 levels across multiple patient samples

  • Integration with exosome isolation platforms for rapid biomarker assessment

  • Real-time monitoring of RPL9 expression in response to therapeutic interventions

• Antibody engineering for enhanced detection:

  • Development of higher-affinity variants for detecting low-abundance RPL9 populations

  • Creation of conformation-specific antibodies that distinguish different functional states

  • Recombinant antibody fragments optimized for specific applications (Fab, scFv)

• Multiplex imaging approaches:

  • Simultaneous detection of RPL9 alongside multiple cancer markers

  • Cyclic immunofluorescence for building comprehensive protein interaction networks

  • Integration with multiplex RNA FISH to correlate protein expression with bound RNA targets

These technological advances are expanding the research toolkit for RPL9 studies, enabling more comprehensive understanding of its roles in normal physiology and disease states, particularly its emerging functions in cancer progression through exosomal pathways .

What are the key considerations for researchers beginning work with RPL9 antibodies?

Researchers initiating studies with RPL9 antibodies should consider these essential factors to ensure experimental success:

• Application-specific antibody selection:

  • Choose appropriate antibody types based on application needs: monoclonal antibodies (68054-1-Ig) provide high specificity for Western blot (1:5000-1:50000 dilution) , while polyclonal antibodies (CAB13632) offer broader epitope recognition for immunofluorescence (1:50-1:200 dilution)

  • Verify reactivity with your species of interest (human, mouse, and rat reactivity is documented)

  • Select antibodies validated for your specific application (WB, IHC, IF/ICC, ELISA)

• Experimental system validation:

  • Validate antibody performance in your specific cell lines or tissues before proceeding to complex experiments

  • Include positive control samples from cell lines with known RPL9 expression (HeLa, HEK-293, HepG2, etc.)

  • Implement proper technical controls (isotype controls, secondary-only controls)

• Protocol optimization:

  • Follow manufacturer-recommended protocols initially, then optimize:

    • For Western blot: test dilution ranges, blocking conditions, and detection methods

    • For IHC/IF: optimize antigen retrieval (TE buffer pH 9.0 is preferred; citrate buffer pH 6.0 is an alternative)

  • Document all optimization steps for reproducibility

• Research question alignment:

  • For ribosome biology: focus on co-localization with other ribosomal components

  • For cancer research: investigate relationship with exosomal pathways and miRNA transport

  • For novel functions: explore interactions with specific miRNAs (miR-24-3p, miR-185-5p)

• Complementary approaches:

  • Combine antibody-based detection with functional assays

  • Implement genetic manipulation approaches (knockdown/overexpression) with validated constructs

  • Consider multi-omics approaches to place findings in broader context

By addressing these considerations systematically, researchers can establish robust experimental foundations for studying RPL9's diverse biological functions.

How should researchers interpret and report findings from RPL9 antibody-based studies?

Proper interpretation and reporting of RPL9 antibody-based research is essential for advancing scientific understanding and ensuring reproducibility:

• Data presentation standards:

  • Include representative images with scale bars for all microscopy

  • Present Western blot data with molecular weight markers clearly indicated

  • Provide quantification of multiple independent experiments with appropriate statistical analysis

  • For clinical samples, report clear inclusion/exclusion criteria and patient demographics

• Controls documentation:

  • Explicitly describe all controls used in the experimental design

  • Include images/data from negative controls (isotype, secondary-only, knockdown samples)

  • Document validation experiments confirming antibody specificity

• Methodological transparency:

  • Provide complete antibody details: source, catalog number, RRID (e.g., AB_2918795) , lot number, dilutions used

  • Detail fixation, permeabilization, and antigen retrieval protocols

  • Specify image acquisition parameters and any post-processing steps

• Data interpretation guidelines:

  • Distinguish between ribosomal and extra-ribosomal functions based on localization and interaction partners

  • Consider context-specific roles (normal tissue vs. cancer models)

  • Acknowledge limitations of antibody-based approaches (potential cross-reactivity, detection thresholds)

• Integration with existing knowledge:

  • Place findings in context of known RPL9 functions in protein synthesis

  • Connect observations to emerging roles in exosomal miRNA transport

  • Discuss implications for broader biological processes (cancer progression, intercellular communication)

• Reproducibility considerations:

  • Provide detailed protocols sufficient for other researchers to replicate findings

  • Consider repository deposition of key datasets and images

  • Disclose any contradictory or unexpected results